Bristol-Myers Squibb Company Revenue in 2024

Bristol-Myers Squibb Company reported $45.0B in revenue for fiscal year 2024. This represents a decline of 2% compared to the 2023 figure of $45.9B.

Revenue of $45 billion in 2024 included a meaningful decline from the $46.1 billion peak in 2022, driven by generic competition for Revlimid — the Celgene-inherited blood cancer drug whose patent protection began eroding precisely on the schedule BMS had anticipated when it made the acquisition. The decline was managed, not catastrophic. The $33 billion in 2023 acquisitions were designed specifically to replace that revenue as it erodes. Net income of $2.9 billion on $45 billion in revenue reflects the enormous weight of the acquisition-and-pipeline-building strategy: $10.5 billion in R&D expenditure, debt service on the Celgene acquisition financing, and ongoing amortization of acquired intangible assets. The gross margin on the actual drug business exceeds 80%; the reported net margin of roughly 6% shows what it costs to maintain a constant acquisition and development cadence. Free cash flow of $12.5 billion provides the clearest view of underlying profitability. The company generated $6 billion in dividends from that cash, demonstrating that it is simultaneously one of the most capital-intensive businesses in the world — spending more on R&D than many entire countries spend on healthcare — and capable of returning substantial capital to shareholders. Revenue history: $46.1 billion in 2022, $45.9 billion in 2023, $45 billion in 2024. The slight sequential decline reflects the Revlimid patent cliff working as predicted. Management's bet is that Karuna's KarXT for schizophrenia, Mirati's KRAS inhibitors, and RayzeBio's radiopharmaceutical platforms will more than replace that revenue before 2028. If they are right, the $33 billion spent in 2023 will look like disciplined capital allocation. If the pipeline disappoints, BMS will need to acquire again.